Helius Medical Technologies

190 articles about Helius Medical Technologies

• Helius Medical Technologies, Inc. Reports Third Quarter 2022 Financial Results

  11/14/2022

  Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended September 30, 2022.

• Helius Medical Technologies, Inc. Announces Participation of Dr. Prue Plummer and MGH Institute of Health Professions to its Therapeutic Experience Program

  11/9/2022

  Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced the participation of Prue Plummer PhD, PT, Professor in the Department of Physical Therapy in the School of Health and Rehabilitation Sciences at the MGH Institute of Health Professions to its Therapeutic Experience Program.

• Helius to Showcase Innovative PoNS Device at ACRM’s 2022 Conference – Demonstrating the Power of Neuromodulation to Help People with MS Improve their Gait

  11/3/2022

  Helius Medical Technologies will showcase its innovative new Portable Neuromodulation Stimulator at the 99th annual American Congress of Rehabilitation Medicine Conference, held November 8-11 in Chicago.

• Helius Medical Technologies, Inc. to Release Third Quarter 2022 Financial Results on November 14, 2022

  11/1/2022

  Helius Medical Technologies, Inc. announced that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022, before the market opens.

• Helius Medical Technologies to Present at the ROTH Capital Partners Inaugural Healthcare Opportunities Conference

  9/29/2022

  Helius Medical Technologies, Inc. announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at the ROTH Capital Partners Inaugural Healthcare Opportunities Conference, as follows.

• Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - September 14, 2022

  9/14/2022

  Helius Medical Technologies, Inc. announced that, effective September 13, 2022, its compensation committee approved an equity award under Helius’ 2021 Inducement Plan, as a material inducement to an individual entering into employment with the Company.

• Helius Medical Technologies to Present at Upcoming Healthcare Investor Conferences in September 2022

  9/6/2022

  Helius Medical Technologies, Inc. announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at two upcoming healthcare conferences as follows.

• Helius Medical Technologies, Inc. Reports Second Quarter 2022 Financial Results

  8/15/2022

  Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended June 30, 2022.

• Helius Medical Technologies, Inc. to Release Second Quarter 2022 Financial Results on August 15, 2022

  8/10/2022

  Helius Medical Technologies, Inc. today announced that the Company will release its second quarter 2022 financial results on Monday, August 15, 2022, after the market closes.

• Helius Medical Technologies, Inc. Announces Pricing of $18 Million Public Offering

  8/5/2022

  Helius Medical Technologies, Inc. today announced the pricing of a public offering of (i) 24,000,000 shares of its Class A common stock (or common stock equivalents in lieu thereof) and (ii) warrants to purchase up to 36,000,000 shares of its Class A common stock (“Public Warrants”) at a purchase price of $0.75 per share,

• Helius Medical Technologies, Inc. Announces Online Training for PoNS Therapy™-- Training for physical therapists treating patients with multiple sclerosis (MS) is now available on demand --

  7/12/2022

  Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the launch of its online training module for physical therapists seeking to treat gait deficit in adults with mild to moderate symptoms of multiple sclerosis (“MS”).

• Helius Medical Technologies, Inc. Presents Poster at the 2022 Consortium of Multiple Sclerosis Centers (“CMSC”) Annual Meeting

  6/6/2022

  Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that a poster detailing the benefits of the Company’s Portable Neuromodulation Stimulator (“PoNS”) Therapy combined with a therapeutic exercise program was presented at the 2022 Consortium of Multiple Sclerosis Centers (“CMSC”) Annual Meeting.

• Helius Medical Technologies, Inc. Announces Launch of Patient Therapy Access Program for PoNS®

  6/1/2022

  Helius Medical Technologies, Inc. announced the launch of its Patient Therapy Access Program, which will provide qualifying patients access to on-label Portable Neuromodulation Stimulator Therapy at a significantly reduced price.

• Helius Medical Announces Poster to Be Presented at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Conference

  5/31/2022

  Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that an abstract highlighting real-world data, which shows the impact of translingual neurostimulation as a rehabilitation therapy to improve gait in people with multiple sclerosis (MS), has been selected for a poster presentation at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Meeting.

• Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - May 24, 2022

  5/24/2022

  Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced that, effective May 23, 2022, its independent directors approved equity awards under Helius’ 2021 Inducement Plan, as a material inducement to four individuals entering into employment with the Company.

• Helius Medical Technologies, Inc. Announces Participation of Dr. Deborah Backus and Shepherd Center in its Therapeutic Experience Program

  5/17/2022

  Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced the addition of Shepherd Center in Atlanta, Georgia to its Therapeutic Experience Program.

• Helius Medical Technologies, Inc. Reports First Quarter 2022 Financial Results and Provides Update on U.S. Commercial Launch of PoNS®

  5/12/2022

  Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, reported financial results for the quarter ended March 31, 2022.

• Helius Medical Technologies, Inc. to Release First Quarter 2022 Financial Results on May 12, 2022

  5/3/2022

  Helius Medical Technologies, Inc. (NASDAQ: HSDT) (TSX: HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the Company will release its first quarter 2022 financial results on Thursday, May 12, 2022, before the markets open.

• Helius Medical Technologies, Inc. Introduces Device in U.S. To Help Multiple Sclerosis Patients Improve Walking Ability

  4/26/2022

  Helius Medical Technologies, Inc. announced availability in the market of its breakthrough technology with the potential to help patients in the United States with Multiple Sclerosis who struggle to walk.

• Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

  3/14/2022

  Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, reported financial results for the quarter and full year ended December 31, 2021.